Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. - Wikidata - awgldk - TriplyDB

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.

http://www.wikidata.org/entity/Q33384088

about

A comprehensive overview of targeted therapy in metastatic renal cell carcinoma From palliative therapy to prolongation of survival: (223)RaCl2 in the treatment of bone metastases Comparative efficacy, tolerability, and survival outcomes of various radiopharmaceuticals in castration-resistant prostate cancer with bone metastasis: a meta-analysis of randomized controlled trials The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer Targeting bone physiology for the treatment of metastatic prostate cancer Radium-223 dichloride in clinical practice: a review.A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial).Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease.Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer.Recent advances in bone-targeted therapies of metastatic prostate cancer Bone-targeting agents in prostate cancer.Evolving role of bone biomarkers in castration-resistant prostate cancer.Preventing bone complications in advanced prostate cancer Outpatient therapeutic nuclear oncology.Beyond Palliation: Therapeutic Applications of 153Samarium-EDTMP.Castration-resistant prostate cancer: new science and therapeutic prospects.Efficacy and safety of a modular multi-modal exercise program in prostate cancer patients with bone metastases: a randomized controlled trial Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.Strengths and Weaknesses of a Planar Whole-Body Method of (153)Sm Dosimetry for Patients with Metastatic Osteosarcoma and Comparison with Three-Dimensional Dosimetry.Overcoming drug resistance and treating advanced prostate cancer Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer.Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer.New and emerging therapies for bone metastases in genitourinary cancers.Samarium-153-ethylene diamine tetramethylene phosphonate, a beta-emitting bone-targeted radiopharmaceutical, useful for patients with osteoblastic bone metastases Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.Radiation safety considerations for the use of ²²³RaCl₂ DE in men with castration-resistant prostate cancer Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival.Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer.Docetaxel-based combination therapy for castration-resistant prostate cancer.Bone metastasis in prostate cancer: emerging therapeutic strategies.Broadening horizons in medical management of prostate cancer.Novel therapeutics for the management of castration-resistant prostate cancer (CRPC).The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases.Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases.Management of metastatic castration-resistant prostate cancer: recent advances.Radium-223 for the treatment of prostate cancer.Optimal therapy sequencing in metastatic castration-resistant prostate cancer.Burden of skeletal-related events in prostate cancer: unmet need in pain improvement.Metabolism and pharmacokinetics of radium-223 in prostate cancer.

P2860

Q24606852-B38C0C4C-C773-420A-B796-D5A66FAA0D33 Q26740064-38C2F241-101A-4F1E-B9A1-790392315A23 Q26785658-86E4423F-C771-42D7-8918-2595AC45D7B0 Q26823733-4638531D-69B0-437C-990E-6F6C04C4653D Q26863249-73197297-FDFF-4B7A-A145-9570BBB9DB4C Q30251496-CBEB6C60-CE15-46BF-A3A5-517E8986855F Q33396382-A30F656F-98A1-4A08-A764-D588FAE19310 Q33405335-C78B1E55-1F90-483D-9060-1DAD0448440D Q33408380-A5C83475-FAB2-485E-9221-FC15F3938F54 Q33703763-83246AF2-53E1-4F39-B7FC-4717A5DFA253 Q33864723-B49A307C-6B42-496C-A17A-EC264D51037A Q34023877-F284898C-8384-46F2-850A-FCB21699E4F2 Q34111634-159FBD31-FF4B-4B4A-B0AD-9B4DBA62B80B Q34244990-7FD98E00-D32E-4DA2-B686-3FCD387332BB Q35057029-0BA2BB30-0B69-4718-B9EF-83969CF3B818 Q35076264-BA277A33-772E-4372-9F09-465FCCE52414 Q35704399-1C6FDC05-5EF6-4896-A795-E93C9AFA3082 Q36087899-9F6A3F41-17B8-44AF-8AB2-CFE4C42EFF21 Q36297804-11475AD0-30BE-407D-9860-9D8FDA103FD0 Q36328812-DF72911A-100C-4770-9A9B-305EBE65B2F5 Q36621348-B28102A1-74A0-4D91-9697-5CEE3B536198 Q36840731-08A91E86-9765-49E3-8869-1A4A1C5D00B9 Q36866291-BD00EE24-F394-4044-A389-D8B2491C69F4 Q37103630-98049AA9-171D-4BF3-BDA0-3526FC9E9B06 Q37166534-528EDECA-B0D6-4A80-A8BF-6BB1A0156C40 Q37168396-7F87170B-D389-4DD1-AE1B-171A02E97B4D Q37193613-8271D21D-9B60-4CC2-B916-F7C40BA11E6F Q37662701-A19F2B07-75A6-426D-8479-C6C0D2561BFA Q37720488-01528035-9A21-4C78-B794-DE05FD1D9BC5 Q37721016-40092C66-910C-4A6B-8C0E-D20B92173698 Q37873719-84A32CE1-9CA5-4047-84EC-36D671976E75 Q37878476-17B7A93F-13C1-4548-B4CA-CA19216D1591 Q37950459-F1771BCF-5A19-461D-9DF9-F867E1A165A7 Q38001275-A98F6CD1-53D6-4364-AA09-9517C2D6AF39 Q38004275-482C32F3-FF73-425A-8C8B-19439ADEB948 Q38012528-557924D2-8771-4157-AF5F-A409C1848EA4 Q38073823-AB501D65-8995-4A0F-9BC3-63BF93DAD1D9 Q38097373-FDA2A031-C1D5-4676-B142-4BA697026223 Q38255741-A6023806-9C84-47D6-8BDF-5591AE34352D Q38367715-DAD1013B-3582-4B64-AA13-BE8F0FC8A25C

P2860

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.

http://www.wikidata.org/entity/Q33384088

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Phase II trial of consolidatio ...... ion-resistant prostate cancer.

@ast

Phase II trial of consolidatio ...... ion-resistant prostate cancer.

@en

type

label

Phase II trial of consolidatio ...... ion-resistant prostate cancer.

@ast

Phase II trial of consolidatio ...... ion-resistant prostate cancer.

@en

prefLabel

Phase II trial of consolidatio ...... ion-resistant prostate cancer.

@ast

Phase II trial of consolidatio ...... ion-resistant prostate cancer.

@en

P1433

Q33384088-EBEFF5BF-1DF4-4B17-9969-002337F46412

P1476

Q33384088-8A8489C8-8F6B-4026-ABCB-66370A1CAE1D

P2093

Q33384088-1CABC9DF-734D-4579-894B-116AF1233A8B

Q33384088-2A9B8523-B9B0-4731-8AAA-C89E6A06D7DF

Q33384088-51C7D364-F189-4930-BDF3-490BEAF933F3

Q33384088-83A73311-FE3D-4EDE-B5A5-39A4A120CF58

Q33384088-85418837-0FCB-4614-B291-F8D44194EBBC

Q33384088-864CAF26-4611-4662-9C4E-0FF5596FA3D6

Q33384088-8D01552D-9B37-4A2B-9611-206ADDC808BC

Q33384088-8EE9522C-8878-488B-A15C-F325C62FC6DF

Q33384088-A1783247-B5C3-4BD4-815E-F386BA292011

Q33384088-C8529C7D-6FEC-41CD-9FA8-A1016B1E5D62

P304

Q33384088-483B913A-F9FA-4FE0-AC8E-3C36E82BB0B8

P31

Q33384088-BE2885B3-A82B-47B6-BEFB-4170CA9F127A

P356

Q33384088-55E69F6F-4A07-4AB0-963E-078E15602CA1

P407

Q33384088-888889B0-A6B4-4F9F-B50B-B6C78FA3195D

P433

Q33384088-925BE286-BF49-47D7-A3E8-A14F738451D2

P478

Q33384088-B9591E32-9D30-46F3-97FD-451C8BA356CD

P50

Q33384088-3C4AFCC4-C607-48AC-B2D7-8AC92A89959E

Q33384088-AB73F322-E8E7-4F1B-8E24-79596A2AAB2E

P577

Q33384088-A8B79BB8-8FCB-4C16-B760-E1E09BB13E87

P698

Q33384088-06A10DEE-8D10-482A-8C70-25BCCF0B32F4

P921

Q33384088-A0EC3F9E-2DD2-4DF2-B90D-7D937BB7D51D

P356

JCO.2008.18.9811

P1433

Journal of Clinical Oncology

P1476

Phase II trial of consolidatio ...... ion-resistant prostate cancer.

@en

P2093

Agnes Laplanche

http://www.w3.org/2001/XMLSchema#string

Christine Theodore

http://www.w3.org/2001/XMLSchema#string

Christophe Massard

http://www.w3.org/2001/XMLSchema#string

Elodie Tournay

http://www.w3.org/2001/XMLSchema#string

Jean Lumbroso

http://www.w3.org/2001/XMLSchema#string

Jeannine Bouzy

http://www.w3.org/2001/XMLSchema#string

Marine Gross-Goupil

http://www.w3.org/2001/XMLSchema#string

Mario Di Palma

http://www.w3.org/2001/XMLSchema#string

Philippe Beuzeboc

http://www.w3.org/2001/XMLSchema#string

Vincent Haddad

http://www.w3.org/2001/XMLSchema#string

P304

2429-2435

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.18.9811

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Bernard Escudier

P577

2009-04-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19364971

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial